These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16920500)

  • 1. MHC class II molecules in tumour immunology: prognostic marker and target for immune modulation.
    Chamuleau ME; Ossenkoppele GJ; van de Loosdrecht AA
    Immunobiology; 2006; 211(6-8):619-25. PubMed ID: 16920500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation.
    Hillman GG; Kallinteris NL; Lu X; Wang Y; Wright JL; Li Y; Wu S; Forman JD; Gulfo JV; Humphreys RE; Xu M
    Cancer Treat Rev; 2004 May; 30(3):281-90. PubMed ID: 15059651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
    Walter W; Lingnau K; Schmitt E; Loos M; Maeurer MJ
    Br J Cancer; 2000 Nov; 83(9):1192-201. PubMed ID: 11027433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of surface HLA-A,B,C molecules in tumour immunity.
    Möller P; Hämmerling GJ
    Cancer Surv; 1992; 13():101-27. PubMed ID: 1423320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy.
    Bonehill A; Heirman C; Thielemans K
    J Gene Med; 2005 Jun; 7(6):686-95. PubMed ID: 15693037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chaperoning antigen presentation by MHC class II molecules and their role in oncogenesis.
    Marsman M; Jordens I; Griekspoor A; Neefjes J
    Adv Cancer Res; 2005; 93():129-58. PubMed ID: 15797446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MHC class II-expressing hepatocytes function as antigen-presenting cells and activate specific CD4 T lymphocyutes.
    Herkel J; Jagemann B; Wiegard C; Lazaro JF; Lueth S; Kanzler S; Blessing M; Schmitt E; Lohse AW
    Hepatology; 2003 May; 37(5):1079-85. PubMed ID: 12717388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The invariant chain transports TNF family member CD70 to MHC class II compartments in dendritic cells.
    Zwart W; Peperzak V; de Vries E; Keller AM; van der Horst G; Veraar EA; Geumann U; Janssen H; Janssen L; Naik SH; Neefjes J; Borst J
    J Cell Sci; 2010 Nov; 123(Pt 21):3817-27. PubMed ID: 20971706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
    Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
    Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insights in antigen processing and epitope selection: development of novel immunotherapeutic strategies for cancer, autoimmunity and infectious diseases.
    Haque A; Blum JS
    J Biol Regul Homeost Agents; 2005; 19(3-4):93-104. PubMed ID: 16602623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The MHC class II-associated invariant chain: a molecule with multiple roles in MHC class II biosynthesis and antigen presentation to CD4+ T cells.
    Bertolino P; Rabourdin-Combe C
    Crit Rev Immunol; 1996; 16(4):359-79. PubMed ID: 8954255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mouse Schwann cells activate MHC class I and II restricted T-cell responses, but require external peptide processing for MHC class II presentation.
    Meyer zu Hörste G; Heidenreich H; Mausberg AK; Lehmann HC; ten Asbroek AL; Saavedra JT; Baas F; Hartung HP; Wiendl H; Kieseier BC
    Neurobiol Dis; 2010 Feb; 37(2):483-90. PubMed ID: 19914379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy.
    Humphreys RE; Hillman GG; von Hofe E; Xu M
    Cell Mol Immunol; 2004 Jun; 1(3):180-5. PubMed ID: 16219165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excessive degradation of intracellular protein in macrophages prevents presentation in the context of major histocompatibility complex class II molecules.
    Brazil MI; Weiss S; Stockinger B
    Eur J Immunol; 1997 Jun; 27(6):1506-14. PubMed ID: 9209504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men.
    Holling TM; Schooten E; van Den Elsen PJ
    Hum Immunol; 2004 Apr; 65(4):282-90. PubMed ID: 15120183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic stellate cells do not exhibit features of antigen-presenting cells.
    Shimizu K; Hashimoto K; Tahara J; Imaeda H; Andoh A; Shiratori K
    Pancreas; 2012 Apr; 41(3):422-7. PubMed ID: 22415667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
    Thompson JA; Dissanayake SK; Ksander BR; Knutson KL; Disis ML; Ostrand-Rosenberg S
    Cancer Res; 2006 Jan; 66(2):1147-54. PubMed ID: 16424052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Class II MHC molecules can use the endogenous pathway of antigen presentation.
    Nuchtern JG; Biddison WE; Klausner RD
    Nature; 1990 Jan; 343(6253):74-6. PubMed ID: 1967486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers.
    Xu M; Lu X; Sposato M; Zinckgraf JW; Wu S; von Hofe E
    Vaccine; 2009 Jul; 27(34):4641-7. PubMed ID: 19520206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of antigen presentation and class II expression by a class II-associated invariant chain peptide.
    Zechel MA; Chaturvedi P; Lee-Chan EC; Rider BJ; Singh B
    J Immunol; 1996 Jun; 156(11):4232-9. PubMed ID: 8666792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.